Resistance to intravenous immunoglobulin in children with Kawasaki disease - Wikidata - awgldk - TriplyDB

Resistance to intravenous immunoglobulin in children with Kawasaki disease

Resistance to intravenous immunoglobulin in children with Kawasaki disease

http://www.wikidata.org/entity/Q36854706

about

Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome Use of corticosteroids during acute phase of Kawasaki disease Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.Novel data-mining approach identifies biomarkers for diagnosis of Kawasaki disease.Important role of CCR2 in a murine model of coronary vasculitis.Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children.A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease Recognition of a Kawasaki disease shock syndrome.Concomitant respiratory viral infections in children with Kawasaki disease.Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system".Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study.FcγR gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response.Recurrent fever syndromes in patients after recovery from Kawasaki syndrome Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance A replication study for association of ITPKC and CASP3 two-locus analysis in IVIG unresponsiveness and coronary artery lesion in Kawasaki disease Abnormal liver panel in acute kawasaki disease Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G Immunoglobulin Resistance in Kawasaki Disease.Evolution of laboratory values in patients with Kawasaki disease.Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia.Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease.Infliximab treatment of pancreatitis complicating acute kawasaki disease IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial)The role of TGF-β and myofibroblasts in the arteritis of Kawasaki disease Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease.Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease.Lymph-node-first presentation of Kawasaki disease compared with bacterial cervical adenitis and typical Kawasaki disease.Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm.Late development of coronary artery abnormalities could be associated with persistence of non-fever symptoms in Kawasaki disease Establishment of Kawasaki disease database based on metadata standard Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population.Management of Kawasaki disease.Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.

P2860

Q24633011-7E6F912E-CFA9-4DEE-8412-267856E88160 Q26765479-CE1022AA-35E0-49D4-A1EB-7AAD8B55A6DA Q26777190-18E113AC-BD47-4299-AA10-57B4AC533FCC Q29417017-0ACABB5D-BACF-4F60-A108-4991EB0739B7 Q30984727-29718C56-356E-447B-8FA2-06346A66BEAC Q31105261-0209ECF5-FA95-43EA-896D-2FB9330ED6BD Q33632324-3C613D9F-E80B-4760-90FC-8A5BA3932324 Q33718985-0735D013-241B-4268-873D-7E30828C5CFF Q33765278-734C011E-EABC-47F9-8D38-6FBCFB71C00E Q34081277-BF2E5F1D-EABD-4352-AB59-0DD7A2CC7B70 Q34088555-3F2AB897-8712-4634-BC2D-6AAD28E125FD Q34253124-4F8A5707-4B77-4BB5-B88A-677AFAD7E026 Q34268298-B45CFC5B-65CF-45AC-8535-BC372D9CFC7D Q34314065-AB68AA9D-E66B-49C5-8C7B-BD863C24731D Q34351750-8E7EE751-3280-40E1-BA84-E5F06EDFFFDE Q34513089-B846BCBD-1C69-4D4B-8378-44BDA03334EB Q34785741-A9BB1888-65B9-4760-9C27-5A7B44782EE6 Q34874251-938A6487-514C-41B3-B96D-F26AE383304F Q34985732-095029CF-DA89-4BC1-B7B6-A67455014948 Q35063963-888347E2-8D7D-4CEF-9AC7-9C2175E09765 Q35193974-E24D5A24-ED0A-4FF4-82C2-43CE9D7BEDC8 Q35569106-04080739-7706-4421-9FF6-8D3E313E12FF Q36086612-DE245DDE-DCF6-4EA1-9FC7-C82C840C812E Q36240217-A857C2DF-00B1-47A8-91F2-4E2EE8A4FB86 Q36240573-219CD7AC-8471-4650-8734-B21FF2A37ACD Q36326783-8D7E777C-EBB9-4A03-9AD8-EA683C5422F1 Q36374231-A431569E-F797-4C2C-BE83-F7530BC9B092 Q36457051-897C52C3-4A97-4C34-939C-FC4611AD447A Q36660337-FE5AEDBA-E64F-41DD-BA72-3759C273B821 Q36731339-EE3D5F5F-119D-47AE-B457-928F1D02AE2D Q36798211-A520C0E8-2529-4401-8869-85E407237F39 Q36849601-F95B3A30-FB67-4201-9EF8-10271C6C83A4 Q37071574-E2378FFD-7BA7-413F-AB05-5172C9107250 Q37129983-4F6A5A02-559C-462F-8FB8-1CF8D5EC0E80 Q37136550-477C5701-0BDA-401C-98B2-83362B491125 Q37175810-B4669B5B-9819-4EEB-898E-C5ECE5912EDF Q37364378-FB60CD4E-9A07-4357-82BA-D95873F55FD2 Q37465500-2E2BF432-BC7F-49C9-9B00-5E20EDA7B08E Q37572983-A36B7D7C-7BD7-43B8-A02D-A62B0B617ABB Q37713300-D76BD049-F4A7-410A-9746-97A41B480A05

P2860

Resistance to intravenous immunoglobulin in children with Kawasaki disease

http://www.wikidata.org/entity/Q36854706

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Resistance to intravenous immunoglobulin in children with Kawasaki disease

@en

type

label

Resistance to intravenous immunoglobulin in children with Kawasaki disease

@en

prefLabel

Resistance to intravenous immunoglobulin in children with Kawasaki disease

@en

P1433

Q36854706-818D8A0E-F287-41CD-86F8-85D4C9126A39

P1476

Q36854706-51280B0E-E096-4D06-87F1-4BE2B4558D97

P2093

Q36854706-0C76B83A-90BB-48CD-8AF4-DC76B27AA10E

Q36854706-173C3024-135A-4CD7-8CD0-F7383CEAD07A

Q36854706-20C7A4C6-CEA4-404F-B1EA-D049E0C2EA3F

Q36854706-24466295-618B-4306-9199-804E40633378

Q36854706-372DC0D7-A1B9-4319-ADB1-2479060B4CB3

Q36854706-4C36BCAE-0E67-4C2D-AEA8-038D4005BD63

Q36854706-8A92B5EA-A4A0-4C28-8B16-C82CCBBCCC22

Q36854706-DF4A39EA-0F7F-45EF-B940-DFC4500FF290

P2860

Q36854706-34DBF898-107D-4109-9044-9269CFBA3CE5

Q36854706-6EF44509-A18F-442A-8DEE-549D05B77EFA

Q36854706-8541781D-C972-425C-A035-2C5CFF56C016

Q36854706-937944AD-0338-4385-9114-6E295B94FDB5

Q36854706-96D9CA04-0424-4925-A19B-BB0C246C3477

Q36854706-A43E0059-A1CE-4EEB-A0DF-4077A439AEEF

Q36854706-B8E9881C-8780-4D3F-87D9-E3B9CD2D85D5

Q36854706-D756B430-B8A5-45F9-8123-55027F93D665

Q36854706-E9579065-B442-4DD3-B289-7ED846FCAF89

Q36854706-FC12B9A5-49B5-42CC-9008-35F87D0CDA74

P304

Q36854706-0D0230E9-E923-4E91-9055-0D34EBCD53CA

P31

Q36854706-5DB26AD0-9084-4474-B7B4-0FA0E0A7B8FF

P356

Q36854706-77E10A68-AE09-4D6D-9FA8-A5CCC429E8BA

P407

Q36854706-C1182395-6A6B-48AD-B2B7-5E80463C90F1

P433

Q36854706-C3A46733-A50F-4B73-9211-3F34D8205C18

P478

Q36854706-399610DA-AB56-4BB7-B47D-DAB93D8EC49F

P50

Q36854706-79FC9CC3-6556-4746-93AD-3D7061F99D51

P577

Q36854706-4A42E3AA-9494-4903-919E-694B3215E962

P5875

Q36854706-CA5FBC97-48F8-4772-8EC2-300374CC67D9

P698

Q36854706-0C1B2E85-18F2-4474-9B45-E353014BD0A4

P932

Q36854706-4D39BCE3-9489-469F-BD55-56CA1D5A0029

P356

J.JPEDS.2007.12.021

P1433

The Journal of Pediatrics

P1476

Resistance to intravenous immunoglobulin in children with Kawasaki disease

@en

P2093

Adriana H Tremoulet

http://www.w3.org/2001/XMLSchema#string

Brookie M Best

http://www.w3.org/2001/XMLSchema#string

Danielle D Martin

http://www.w3.org/2001/XMLSchema#string

Elena Corinaldesi

http://www.w3.org/2001/XMLSchema#string

Jane C Burns

http://www.w3.org/2001/XMLSchema#string

Julia R Eichenfield

http://www.w3.org/2001/XMLSchema#string

Sungchan Song

http://www.w3.org/2001/XMLSchema#string

Susan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis, treatment, and long-term management of Kawasaki disease

Infliximab treatment for refractory Kawasaki syndrome

Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy

Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand

Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease.

A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.

Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.

Gamma globulin re-treatment in Kawasaki disease.

P304

117-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPEDS.2007.12.021

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P50

Jane W. Newburger

P577

2008-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5284029

http://www.w3.org/2001/XMLSchema#string

P698

18571548

http://www.w3.org/2001/XMLSchema#string

P932

2526555

http://www.w3.org/2001/XMLSchema#string